

## Vietnam Support for Pentavalent Vaccine

**This Decision Letter sets out the Programme Terms of a Programme**

<b>1. Country:</b> Vietnam				
<b>2. Grant number:</b> 1719-VNM-04a-X / 08-VNM-08c-Y / 18-VNM-04g-Y				
<b>3. Date of Decision Letter:</b> 26 June 2018				
<b>4. Date of the Partnership Framework Agreement (PFA):</b> 9 October 2013				
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine				
<b>6. Vaccine type:</b> Pentavalent				
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID (2009-2018); DTP-HepB-Hib, 10 dose(s) per vial, LIQUID (2018 onward)				
<b>8. Programme duration<sup>1</sup>:</b> 2009 -2019				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)				
	<b>2009-2017</b>	<b>2018</b>	<b>2019</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	87,462,371 <sup>3</sup>	966,500	777,500	89,206,371
<b>10. Vaccine introduction grant (in US\$):</b> 492,500 already disbursed on 23 Sept 2008				
<b>11. Product switch grant (in US\$):</b> 117,870				
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the PFA) <sup>4</sup>				
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2009-2017</b>	<b>2018</b>		
Number of Pentavalent vaccines doses		833,200		
Annual Amounts (US\$)	87,462,371 <sup>5</sup>	966,500		
<b>13. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
<b>14. Self-procurement:</b> Not applicable				

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**15. Co-financing obligations:** Reference code: 1719-VNM-04a-X-C

According to the co-financing policy, the Country falls within the group Accelerated transition as of 1 January 2015. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019
Number of vaccine doses	4,646,500	5,085,700
Number of AD syringes	4,861,500	
Number of re-constitution syringes		
Number of safety boxes	53,500	
Value of vaccine doses (US\$)	5,018,145	
Total co-financing payments (US\$) (including freight)	5,607,500	US\$5,985,500

**16. Operational support for campaigns:** Not applicable

**17. Additional reporting requirements:**

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**18. Financial clarifications:** Not applicable

**19. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
26 June 2018